Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.La Jolla Pharmaceutical has signed two exclusive worldwide license agreements for the intellectual property rights covering its next-generation gentamicin derivatives, LJPC-30Sa and LJPC-30Sb.
Subscribe to our email newsletter
The first license agreement is with the Indiana University Research and Technology Corporation (IURTC) and the second is with the IURTC and the University of Alabama at Birmingham (UAB), both follow from the previously announced option agreements.
These agreements cover the use of LJPC-30Sa and LJPC-30Sb as antimicrobial agents and for the potential treatment of rare genetic disorders.
Gentamicin, which has become one of the most commonly prescribed hospital antibiotics, consists primarily of a mixture of four distinct but closely related chemical entities that may contribute differentially to the product’s toxicity profile.
Both LJPC-30Sa and LJPC-30Sb are purified components of the currently marketed gentamicin product that retain the biologic activity of gentamicin, yet appear to lack the traditional kidney toxicity associated with it.
The company intends to pursue a dual development strategy with its next-generation gentamicin derivative program.
In addition to the potential treatment of serious bacterial infections, the company also plans to develop LJPC-30Sa and LJPC-30Sb for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
The US Food and Drug Administration (FDA) has also granted approval to the company following a pre-investigational new drug application (IND) meeting to proceed with a proposed Phase I clinical trial following the submission of an IND.